We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
May 10, 2023
Crinetics Announces May 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces May 2023 inducement grants: the stock options were granted as inducements material to nine employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
May 4, 2023
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Crinetics Pharmaceuticals reported financial results and provided an update on first quarter 2023 clinical progress
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:
- Acromegaly
- Carcinoid syndrome
- Congenital hyperinsulinism (congenital HI)
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
- PTH Antagonist
- Hyperparathyroidism
- Polycystic kidney
- TSH Antagonist
- Grave’s disease
- TED
- Diabetes
- Obesity
Our once-daily, oral, investigational drug for the treatment of acromegaly is in Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)